Literature DB >> 8413956

Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease.

M C Patterson1, M Horowitz, R B Abel, J N Currie, K T Yu, C Kaneski, J J Higgins, R R O'Neill, P Fedio, A Pikus.   

Abstract

Type 3 neuronopathic Gaucher's disease (GD3) is phenotypically heterogeneous. In many GD3 patients, progressive myoclonus and dementia dominate the illness, with death secondary to progressive CNS disease. We have designated this group as GD3a. We studied 14 children with Gaucher's disease, isolated horizontal supranuclear gaze palsy, and aggressive systemic disease, and designated this group as GD3b. In comparison with 13 children with type 1 non-neuronopathic Gaucher's disease, the GD3b children presented earlier, and were shorter, underweight, and more prone to cardiopulmonary, hepatic, and skeletal complications. One-half of the children died in childhood or adolescence of systemic complications. Patients with at least one copy of the mutation that causes substitution of asparagine for serine at amino acid 370 of glucocerebrosidase did not develop neurologic signs. Patients homoallelic for the mutation causing substitution of leucine for proline at position 444 had severe systemic disease; neurologic signs were frequently, but not invariably, present. Early diagnosis and timely enzyme replacement therapy promise to improve the prognosis in GD3b.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8413956     DOI: 10.1212/wnl.43.10.1993

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  29 in total

Review 1.  Management of neuronopathic Gaucher disease: a European consensus.

Authors:  A Vellodi; B Bembi; T B de Villemeur; T Collin-Histed; A Erikson; E Mengel; A Rolfs; A Tylki-Szymanska
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

2.  No justification for very high-dose enzyme therapy for patients with type III Gaucher disease.

Authors:  Ari Zimran; Deborah Elstein
Journal:  J Inherit Metab Dis       Date:  2007-11       Impact factor: 4.982

Review 3.  Variable clinical presentation in lysosomal storage disorders.

Authors:  M Beck
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

4.  Radiographic findings in type 3b Gaucher disease.

Authors:  S C Hill; B M Damaska; M Tsokos; C Kreps; R O Brady; N W Barton
Journal:  Pediatr Radiol       Date:  1996-12

Review 5.  Gaucher disease.

Authors:  Aabha Nagral
Journal:  J Clin Exp Hepatol       Date:  2014-04-21

Review 6.  Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease.

Authors:  R O Brady; G J Murray; N W Barton
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

7.  Intermittent horizontal saccade failure ('ocular motor apraxia') in children.

Authors:  C M Harris; F Shawkat; I Russell-Eggitt; J Wilson; D Taylor
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

8.  Clinical and molecular characteristics of Japanese Gaucher disease.

Authors:  Y Eto; H Ida
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

9.  Echocardiographic Assessment of Left Ventricular Function in Type 1 Gaucher's Disease.

Authors:  Mirta Kozelj; Samo Zver; Vesna Zadnik
Journal:  Adv Hematol       Date:  2010-07-20

10.  Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

Authors:  Deborah Elstein; Ari Zimran
Journal:  Biologics       Date:  2009-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.